CO2 Lock Corp. Closes $1.1M Financing and Provides Technical Update on Activities at Carbon Capture and Storage Site in Canada
Vancouver, British Columbia–(Newsfile Corp. – September 21, 2023) – CO2 Lock Corp. (“CO2 Lock” or…
Vancouver, British Columbia–(Newsfile Corp. – September 21, 2023) – CO2 Lock Corp. (“CO2 Lock” or…
Vancouver, British Columbia–(Newsfile Corp. – September 21, 2023) – Hypercharge Networks Corp. (NEO: HC) (OTCQB: HCNWF)…
Ucore announces: Industrial Tax Exemption Program (“ITEP”) approval from the Louisiana Board of Commerce and…
Reyna Law Firm has moved to update its damage claim assistance services for those recuperating…
Incorporated Insurance Services (IIS) is a premier destination for comprehensive and affordable auto insurance. Sherman…
ZUG, SWITZERLAND / ACN Newswire / September 21, 2023 / The first of its kind,…
NEW DELHI, Sept 21, 2023 – (ACN Newswire) – Excitement surrounds Trescon’s Digital Acceleration &…
NEW YORK–(BUSINESS WIRE)–VanEck today announced the launch of the VanEck Office and Commercial REIT ETF…
Collaboration across entire LNG value chain vital to scaling up supply of green fuels on…
PROVIDENCE, R.I.–(BUSINESS WIRE)–Citizens Financial Group (NYSE: CFG) announced today that its Citizens Bank, N.A. subsidiary…
New Products and Updates Simplify Model-Based Design for Engineers and Researchers in the Aerospace, Automotive,…
For no additional fee, SumUp One subscribers can now receive their SumUp funds by 7AM…
Users get full access to the platform, including StreamSets Data Collector and StreamSets Transformer for…
Full commercial launch of NexoBrid marks important first step to becoming the new standard of…
Full commercial launch of NexoBrid marks important first step to becoming the new standard of…
Paris, France, September 21, 2023 – Coave Therapeutics (‘Coave’), a genetic medicine company focused on…
Paris, France, September 21, 2023 – Coave Therapeutics (‘Coave’), a genetic medicine company focused on…
— LunAIRo Compares AD109 to Placebo Over 6 and 12 Months in People with OSA…
— LunAIRo Compares AD109 to Placebo Over 6 and 12 Months in People with OSA…
NEW YORK, Sept. 21, 2023 (GLOBE NEWSWIRE) — Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in…